Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jazz Pharma Plc (NQ: JAZZ )

126.67 +1.57 (+1.25%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharma Plc

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Jazz Q4 2022 Revenue Grows 8% To $972M, Provides Outlook
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) Q4 2022 revenue was $972.12 million an 8% increase compared to 896.73 million in Q4 2021. Financial Highlights 
Via Benzinga
Earnings Scheduled For March 1, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. 
Via Benzinga
Earnings Preview For Jazz Pharmaceuticals
Via Benzinga
Cannabis-Based Medicine As A Potential Treatment For Psychosis, An Oxford University Study Says
The Department of Psychiatry at the University of Oxford will conduct an international study to investigate whether cannabis-based medicine can treat psychosis. 
Via Benzinga
Teva Plots Its Knockoff Of Axsome's New Depression Drug, Sending The Biotech Sprawling
The company only just gained approval for its depression drug in August. 
Via Investor's Business Daily
GlycoMimetics Audio Discussion And Analysis With Dan Cohen And Scott Matusow
Dan Cohen and Scott Matusow discuss In this 1:11 audio the upcoming data sets for Glycomimetics. We talk about The Company's platform chemistry in depth, and give our predictions for success/failure of... 
Via Talk Markets
2 Cannabis Stocks That Could Make You Richer
These two stocks could grow like weeds in the next five years and beyond. 
Via The Motley Fool
Will Investors Notice Exciting Sign On Jazz Pharmaceuticals's Chart?
Via Benzinga
2 Cannabis Stocks to Buy for the Long Haul
Don't give up on this sector too quickly. 
Via The Motley Fool
Jazz Pharma Opts In, Advances Zanidatamab Partnership With Zymeworks
Via Benzinga
CBD-Based Life-Changing Drug For Tuberous Sclerosis Patients, Epidiolex, Now Available Via England's NHS
The National Health Service England confirmed Tuesday that starting this week, doctors can prescribe Jazz Pharmaceuticals (NASDAQ: JAZZ) Epidiolex, a CBD-based medicine, to patients suffering from... 
Via Benzinga
3 Cannabis Stocks With Double-Digit Percentage Revenue Growth
Their shares may be down, but their sales are up. 
Via The Motley Fool
The Ultimate Growth Stocks to Buy With $300 Right Now
These three companies should deliver inflation-busting long-term growth. 
Via The Motley Fool
2 Promising New Growth Stocks to Watch in 2023
These stocks have plenty of room to run. 
Via The Motley Fool
Jazz Pharma, Zymeworks Highlight 84% Overall Survival At 18 Months From Zanidatamab In Esophageal Cancer
Via Benzinga
6 Analysts Have This to Say About Jazz Pharmaceuticals
Via Benzinga
What 6 Analyst Ratings Have To Say About Jazz Pharmaceuticals
Via Benzinga
2 Stocks That Beat the Market in 2022 and That Analysts Think Can Go Higher
There are still plenty of growth opportunities left for these businesses. 
Via The Motley Fool
These Stocks Jumped 100% and 30% Last Year. Here's Why They're Still a Buy.
These stocks look cheap if you take a long-term view. 
Via The Motley Fool
Jazz Pharmaceuticals Files Patent Infringement Against Generic Drugmakers In New Jersey's District Court
Jazz Pharmaceuticals (NASDAQ: JAZZ), a drug company behind the CBD-based medication Epidiolex, recently filed a lawsuit against Teva Pharmaceutical Industries Ltd (NYS 
Via Benzinga
2 Growth Stocks to Buy Heading Into 2023
These biotechs are far from having achieved their full potential. 
Via The Motley Fool
2 Top Biotech Stocks to Buy for the Long Haul
These mid-cap biotechs are solid long-term choices. 
Via The Motley Fool
Better Buy: Moderna vs Axsome
Revenue prospects look promising for both of these biotech companies. 
Via The Motley Fool
Tesla, Amazon, Micron, Sintx, Zymeworks: Why These 5 Stocks Are Drawing Investors' Attention Today
U.S. markets soared on Wednesday as consumer confidence surged to an eight-month high in December following a drop in inflation and the labor market remaining strong. Twelve-month inflation... 
Via Benzinga
After Jumping 100%, Is Axsome a Buy Before 2023?
Axsome's revenue story is just getting started. 
Via The Motley Fool
Netflix To Rally Around 29%? Here Are 10 Other Price Target Changes For Friday
Wells Fargo raised Netflix, Inc. (NASDAQ: NFLX) price target from $300 to $400. Wells Fargo also upgraded the stock from Equal Weight to Overweight. Netflix shares rose 0.6% to close at $310.26 on... 
Via Benzinga
2 Unstoppable Growth Stocks to Buy in 2022 and Beyond
These biotech players beat the bear market this year. 
Via The Motley Fool
3 Fierce Stocks That Are Screaming Buys in December
Here are three winners in the making. 
Via The Motley Fool
Jazz Caregiver Survey: CBD-Based Epidiolex Improves Seizure & Non-Seizure Outcomes In Patients With Severe Epilepsy
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced new real-world data from the BECOME (BEhavior, COgnition, and More with Epidiolex) caregiver survey that showed a substantial proportion of caregivers... 
Via Benzinga
Biotech Space Offers Reward In 2023 Despite Economic Risks
Despite the economic headwinds, the mid-to long-term outlook for the biotech space remains strong, and investors who are able to take advantage of undervalued biotech stocks may be well-positioned for... 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.